1. Disease Information

1.1 Concise overview

Susac syndrome is a rare, immune-mediated, ischemia-producing occlusive microvascular endotheliopathy that affects the brain, retina, and inner ear, producing a characteristic clinical triad of encephalopathy/central nervous system dysfunction, branch retinal artery occlusions (BRAO), and sensorineural hearing loss. (bose2023susacsyndromeneurological pages 1-2, jarius2014clinicalparaclinicaland pages 1-2, bullock2023useofdisease pages 1-2)

1.2 Synonyms / alternative names

• Susac syndrome / Susac’s syndrome (jarius2014clinicalparaclinicaland pages 1-2)
• Retinocochleocerebral syndrome (concept consistent with tri-organ involvement; commonly used term in the literature though not explicitly enumerated in the extracted snippets) (bose2023susacsyndromeneurological pages 1-2, david2022susacsyndromea pages 1-2)

1.3 Evidence source type

Most available evidence is derived from: - Case reports and case series, reflecting rarity (jarius2014clinicalparaclinicaland pages 1-2, bose2023susacsyndromeneurological pages 1-2) - Retrospective cohorts (fuchs2025clinicalcharacterizationand pages 1-2) - Prospective observational cohorts / registries and biomarker studies on ClinicalTrials.gov (NCT01273792 chunk 1, NCT01481662 chunk 1, NCT06881368 chunk 1)

2. Etiology

2.1 Disease causal factors (mechanistic)

Current evidence supports SuS as a primarily immune-mediated endotheliopathy of small vessels, with converging support for CD8+ cytotoxic T-cell (CTL)–mediated endothelial injury and (in a subset) humoral/complement involvement. (gross2019cd8+tcellmediated pages 1-2, bose2023susacsyndromeneurological pages 1-2, jarius2014clinicalparaclinicaland pages 1-2)

Direct abstract quote (mechanism; primary literature): - Gross et al. (Nature Communications, 2019) report: “CTLs adhere to CNS microvessels … and polarize granzyme B, which most likely results in the observed endothelial cell injury and microhemorrhages” and that “Blocking T-cell adhesion by anti-α4 integrin-intervention ameliorates the disease in the preclinical model.” (gross2019cd8+tcellmediated pages 1-2)

2.2 Risk factors

Demographic risk: young adult onset and female predominance are repeatedly observed in cohorts/series. (david2022susacsyndromea pages 1-2, seifertheld2017susacssyndromeclinical pages 6-10)

Possible infectious triggers (limited evidence): In an Israeli series of 7 patients, recent cytomegalovirus (CMV) exposure was “serologically evident in three patients,” and one had a high antistreptolysin titer—interpreted as potentially supporting a post-infectious mechanism (observational association, not proof of causality). (wilfyarkoni2020increasedincidenceof pages 2-3)

2.3 Protective factors

No protective genetic or environmental factors were identified in the retrieved evidence.

2.4 Gene–environment interactions

No gene–environment interactions were identified in the retrieved evidence.

3. Phenotypes

3.1 Core phenotype triad (with suggested HPO terms)

1. Brain involvement / encephalopathy: confusion, cognitive dysfunction, behavioral/psychiatric features, focal neurological symptoms, headache.
2. HPO suggestions: Encephalopathy; Cognitive impairment; Headache; Behavioral abnormality; Confusion; Focal neurological deficit.

3. Frequency examples: encephalopathy is part of triad; in one 16-patient series, encephalopathy occurred at some point in most patients but was present at onset in 6/16 (37.5%). (bose2023susacsyndromeneurological pages 1-2)

4. Retinal involvement: BRAO, arterial wall hyperfluorescence (AWH), visual field defects; may be clinically silent.

5. HPO suggestions: Branch retinal artery occlusion; Visual field defect; Scotoma; Visual impairment.

6. In a 16-patient series, objective retinal ischemia was documented in ~11/16. (bose2023susacsyndromeneurological pages 6-8)

7. Vestibulocochlear involvement: sensorineural hearing loss, tinnitus, vertigo/balance problems.

8. HPO suggestions: Sensorineural hearing impairment; Tinnitus; Vertigo.
9. In the 16-patient series, hearing loss occurred in 12/16 (75%) at any stage. (bose2023susacsyndromeneurological pages 6-8)

3.2 Neurocognitive and neuropsychiatric manifestations (2024 review)

A 2024 review highlights that cognitive deficits range from subtle to profound, with executive function and short-term recall frequently affected; psychiatric manifestations may include anxiety, mood disorders, or psychosis, and attribution may be confounded by steroid side effects. (koncz2024theneurocognitiveand pages 1-2)

Direct abstract quote (2024 review): “Executive function and short-term recall are affected frequently. Psychiatric manifestations may be absent or may include anxiety, mood disorders or psychosis.” (koncz2024theneurocognitiveand pages 1-2)

3.3 Phenotype characteristics (onset, progression)

• Onset pattern: often subacute with headache and focal deficits (75% in one 16-patient series). (bose2023susacsyndromeneurological pages 1-2)
• Triad completeness at onset: often incomplete; 13% at first presentation in the 16-patient series, but 80% eventually developed the triad. (bose2023susacsyndromeneurological pages 6-8)

3.4 Quality-of-life impact

Functional impairment is substantial in a subset. In a 20-patient multicenter cohort, ~50% resumed employment while 25% did not return to work. (fuchs2025clinicalcharacterizationand pages 1-2)

4. Genetic / Molecular Information

4.1 Causal genes / pathogenic variants

No causal genes or pathogenic germline variants were identified in the retrieved evidence; SuS is not established as a monogenic disorder in these sources.

4.2 Modifier genes, epigenetics, chromosomal abnormalities

No evidence identified in the retrieved texts.

5. Environmental Information

• Environmental exposures: An Israeli case series explicitly reported that toxic environmental exposure was not reported and no common demographic characteristics were found. (wilfyarkoni2020increasedincidenceof pages 2-3)
• Lifestyle factors: not described in the extracted evidence.
• Infectious agents: limited observational association with CMV/streptococcal serology in a small series. (wilfyarkoni2020increasedincidenceof pages 2-3)

6. Mechanism / Pathophysiology

A current working model is that immune dysregulation causes microvascular endothelial injury and occlusion leading to ischemia in brain/retina/inner ear.

6.1 Proposed mechanistic chain (upstream → downstream)

1. Activated cytotoxic CD8+ T cells expand and target microvessels (oligoclonal expansion; activated phenotype). (gross2019cd8+tcellmediated pages 1-2)
2. CTL adhesion to microvessels with granzyme B polarization causes endothelial injury and microhemorrhages. (gross2019cd8+tcellmediated pages 1-2)
3. In a subset, AECA (complement-activating IgG1) may contribute to microvascular injury. (jarius2014clinicalparaclinicaland pages 1-2)
4. Complement deposition is seen in tissue in some cases (C4d deposition in ~30% of vessels in one series), supporting a humoral component. (bose2023susacsyndromeneurological pages 1-2)
5. Microinfarcts and ischemic lesions develop in affected organs, producing the clinical triad. (bose2023susacsyndromeneurological pages 1-2, david2022susacsyndromea pages 1-2)

A structured mechanism table (cell types, GO/CL suggestions) is provided below.

Table: This table summarizes the current mechanistic model of Susac syndrome, from upstream immune injury to downstream ischemic damage in brain, retina, and cochlea. It is useful for knowledge-base curation because it links causal steps, cell types, ontology suggestions, and primary evidence.

6.2 Targetability and translational implications

Gross et al. provide mechanistic and translational evidence that blocking α4-integrin–mediated T-cell adhesion can ameliorate disease in a preclinical model and report decreased severity in four treated patients (observational), highlighting leukocyte trafficking as a therapeutic target. (gross2019cd8+tcellmediated pages 1-2)

7. Anatomical Structures Affected

7.1 Organ level (with UBERON suggestions)

• Brain/CNS (UBERON: brain; meninges) → encephalopathy, headache, focal deficits, cognitive/psychiatric symptoms. (bose2023susacsyndromeneurological pages 1-2, david2022susacsyndromea pages 1-2)
• Eye/retina (UBERON: retina; retinal artery) → BRAO/AWH, visual field defects, sometimes silent involvement. (cvikova2024casereportsusac pages 7-8, fuchs2025clinicalcharacterizationand pages 1-2)
• Inner ear/cochlea + semicircular canals (UBERON: cochlea; vestibular apparatus) → SNHL, tinnitus, vertigo. (bose2023susacsyndromeneurological pages 1-2, cvikova2024casereportsusac pages 7-8)

7.2 Tissue/cell level (CL suggestions)

• Vascular endothelium (CL: endothelial cell) is the main target. (bose2023susacsyndromeneurological pages 1-2, gross2019cd8+tcellmediated pages 1-2)
• CD8+ T cells (CL: CD8-positive alpha-beta T cell) are strongly implicated. (gross2019cd8+tcellmediated pages 1-2)

7.3 Subcellular / molecular compartments

Not specifically described in the retrieved evidence.

8. Temporal Development

8.1 Onset and course

SuS may follow monocyclic/monophasic, polycyclic, or chronic-continuous courses. (bose2023susacsyndromeneurological pages 8-9, vodopivec2016treatmentofsusac pages 1-3)

8.2 Relapse timing

In a 20-patient cohort, cerebral and inner-ear exacerbations were most common in the first year, whereas retinal exacerbations occurred more frequently mainly within the first 2 years. (fuchs2025clinicalcharacterizationand pages 1-2)

8.3 Diagnostic delay

Diagnostic delay is common due to incomplete triad at onset; a UK series reported mean time to diagnosis of 3 months. (bose2023susacsyndromeneurological pages 6-8)

9. Inheritance and Population

9.1 Epidemiology (recent quantitative estimates)

A nationwide Austrian survey (adults >19 years) estimated: - Annual incidence: 0.024 per 100,000 (95% CI 0.010–0.047)
- Minimum 5-year period prevalence: 0.148 per 100,000 (95% CI 0.071–0.272) (seifertheld2017susacssyndromeclinical pages 6-10)

9.2 Demographics

• Female predominance is typical (e.g., female:male 3:1 in one 16-patient series). (bose2023susacsyndromeneurological pages 1-2)
• Mean onset in the 20–40 range is common across studies; for example mean age 35.6 in Bose et al., and mean onset 38.9 in a later multicenter cohort. (bose2023susacsyndromeneurological pages 1-2, fuchs2025clinicalcharacterizationand pages 1-2)

A structured table of key statistics is provided below.

Table: This table summarizes high-yield epidemiology, diagnostic timing, prognosis, and serologic findings for Susac syndrome from major cohort and multicenter studies. It is useful for quickly comparing incidence, demographic patterns, functional outcomes, and AECA-related mechanistic evidence.

10. Diagnostics

10.1 Clinical criteria

A practical widely cited approach is the European Susac Consortium (EuSaC) 2016 criteria, which define brain, retinal, and vestibulocochlear involvement with specific required clinical/imaging findings, yielding definite/probable/possible diagnoses. (cvikova2024casereportsusac pages 7-8, cvikova2024casereportsusac media 1cd8097f)

10.2 Key tests and real-world implementation

Modern practice emphasizes multimodal confirmation: - Brain MRI (callosal/pericallosal lesions; “snowballs”) (bose2023susacsyndromeneurological pages 1-2) - Fluorescein angiography (BRAO/AWH) and OCT/SD-OCT (cvikova2024casereportsusac pages 7-8, wilfyarkoni2020increasedincidenceof pages 2-3) - Audiogram ± vestibular testing (cvikova2024casereportsusac pages 7-8, fuchs2025clinicalcharacterizationand pages 1-2) - CSF (typically raised protein; OCB usually absent) (bose2023susacsyndromeneurological pages 1-2, cvikova2024casereportsusac pages 7-8)

A structured diagnostic/workflow table (with ontology suggestions) is provided below.

Table: This table summarizes the main diagnostic domains, tests, and real-world workflow for Susac syndrome, including imaging, ophthalmic, audiologic, and CSF findings. It is useful as a knowledge-base-ready quick reference linking practical clinical actions with ontology suggestions and primary sources.

10.3 Visual evidence (table/figures)

• EuSaC diagnostic criteria table and example imaging (MRI “snowballs”; retinal angiography features) were extracted from a 2024 Frontiers in Neurology paper. (cvikova2024casereportsusac media 1cd8097f, cvikova2024casereportsusac media 4d784135, cvikova2024casereportsusac media bcac5361, cvikova2024casereportsusac media 5a95f86e)

10.4 Differential diagnosis (examples noted in protocols)

Prospective cohort protocols explicitly exclude key mimics such as multiple sclerosis, CADASIL, mitochondrial disease, CNS tumors, and Lyme disease, reflecting real-world diagnostic workups. (NCT06881368 chunk 2, NCT01481662 chunk 1)

11. Outcome / Prognosis

11.1 Functional outcomes

In a multicenter cohort (n=20): - Cognitive function improved in 75% during follow-up. (fuchs2025clinicalcharacterizationand pages 1-2) - ~50% resumed employment; 25% did not return to work, indicating persistent morbidity in a substantial subset. (fuchs2025clinicalcharacterizationand pages 1-2)

11.2 Prognostic factors

Severe cerebral involvement at onset, male sex, and elevated CSF protein were associated with worse prognosis in disability/dependency in one multicenter study. (fuchs2025clinicalcharacterizationand pages 1-2)

12. Treatment

12.1 Current approach (evidence type: expert consensus + observational)

There are no randomized controlled trials; treatment is guided by expert consensus, retrospective series, and analogy to other immune-mediated microvascular diseases. (fuchs2025clinicalcharacterizationand pages 1-2, david2022susacsyndromea pages 4-5)

Commonly described regimens include: - High-dose corticosteroids (e.g., IV methylprednisolone induction followed by slow taper) (david2022susacsyndromea pages 4-5, bose2023susacsyndromeneurological pages 1-2) - IVIG as induction/relapse management or adjunct, often used more frequently in relapsing disease (bose2023susacsyndromeneurological pages 1-2, david2022susacsyndromea pages 4-5) - Escalation/maintenance immunosuppression: mycophenolate mofetil, azathioprine, cyclophosphamide, rituximab (david2022susacsyndromea pages 4-5, cvikova2024casereportsusac pages 7-8) - Adjunct antiplatelet therapy is frequently used (e.g., aspirin noted in an Austrian cohort; antiplatelet agents frequently used in reviews). (seifertheld2017susacssyndromeclinical pages 6-10, david2022susacsyndromea pages 4-5)

12.2 Treatment strategy / algorithm (real-world)

A 2023 UK series proposed a severity- and response-guided therapeutic algorithm based on long-term management experience, emphasizing early aggressive therapy in severe cases to reduce morbidity/disability. (bose2023susacsyndromeneurological pages 1-2)

12.3 Suggested MAXO terms (examples; to be mapped in ontology curation)

• High-dose glucocorticoid therapy; Intravenous immunoglobulin therapy; Immunosuppressive therapy; B-cell depletion therapy (rituximab); Therapeutic plasma exchange; Antiplatelet therapy.

13. Prevention

No established primary prevention is described in the retrieved evidence. Given rarity and unclear triggers, prevention focuses on: - Secondary/tertiary prevention via early recognition and aggressive treatment to prevent irreversible brain/retinal/cochlear damage. (bose2023susacsyndromeneurological pages 1-2, bullock2023useofdisease pages 1-2)

14. Other Species / Natural Disease

No naturally occurring SuS analog in non-human species was identified in the retrieved evidence.

15. Model Organisms

A transgenic mouse model recapitulating key features of SuS-like CTL-mediated endotheliopathy was reported in a major mechanistic study and was used to demonstrate benefit of anti-α4 integrin intervention. (gross2019cd8+tcellmediated pages 1-2)

Recent developments (prioritizing 2023–2024)

1. Diagnostic sharpening and multimodal workflows (2023–2024):
2. 2023 long-term UK experience emphasized “red flags,” characteristic callosal MRI lesions, and the need for ophthalmic FA/OCT because eye involvement may be subtle/silent. (bose2023susacsyndromeneurological pages 1-2)

3. 2024 Frontiers review emphasizes black-blood vessel-wall MRI and provides a concise operationalization of EuSaC criteria and updated imaging prevalence ranges. (cvikova2024casereportsusac pages 7-8)

4. Neuropsychiatric/cognitive phenotype focus (2024):

5. 2024 review highlights gaps in standardized cognitive phenotyping and calls for longitudinal data capture and treatment-outcome correlations in neuropsychiatric domains. (koncz2024theneurocognitiveand pages 1-2)

6. Real-world research infrastructure (ongoing):

7. Multiple prospective observational cohorts and biomarker studies are active/registered (France AP-HP CARESS cohorts; Charité biomarker study), indicating field-wide movement toward standardized phenotyping, biospecimen banking, and imaging biomarkers (DTI, OCT, MRI). (NCT01273792 chunk 1, NCT01481662 chunk 1, NCT06881368 chunk 1)

Current applications / real-world implementations

• Clinical implementation of multimodal triad testing: brain MRI + fluorescein angiography/OCT + audiometry/vestibular testing is explicitly used in real-world cohorts and is also embedded in prospective registries/trials. (wilfyarkoni2020increasedincidenceof pages 2-3, NCT01481662 chunk 1)
• Monitoring tools and biomarkers: fluorescein angiography is described as an excellent biomarker of retinal disease activity, though not necessarily reflective of brain/ear activity; formal symptom/damage scoring tools have been proposed to standardize longitudinal assessment. (bullock2023useofdisease pages 1-2)

Evidence limitations (for knowledge-base curation)

• Coding identifiers (Orphanet/MONDO/MeSH/ICD/OMIM) were not extractable from the retrieved full text; populate via direct terminology database lookup.
• Many treatment conclusions rely on observational evidence and expert opinion; RCTs are not available in retrieved sources. (david2022susacsyndromea pages 4-5, fuchs2025clinicalcharacterizationand pages 1-2)
• Genetic causality is not established in these sources.

URLs and publication dates (examples of key sources cited)

• Bose et al. Journal of Neurology — Published online 22 Aug 2023. https://doi.org/10.1007/s00415-023-11891-z (bose2023susacsyndromeneurological pages 1-2)
• Koncz et al. Neurological Sciences — Published online 2 Jul 2024. https://doi.org/10.1007/s10072-024-07672-9 (koncz2024theneurocognitiveand pages 1-2)
• Cviková et al. Frontiers in Neurology — Feb 2024. https://doi.org/10.3389/fneur.2024.1339438 (cvikova2024casereportsusac pages 7-8)
• Gross et al. Nature Communications — 2019. https://doi.org/10.1038/s41467-019-13593-5 (gross2019cd8+tcellmediated pages 1-2)
• Jarius et al. Journal of Neuroinflammation — 2014. https://doi.org/10.1186/1742-2094-11-46 (jarius2014clinicalparaclinicaland pages 1-2)
• Seifert-Held et al. International Journal of Neuroscience — Sep 2017. https://doi.org/10.1080/00207454.2016.1254631 (seifertheld2017susacssyndromeclinical pages 6-10)
• ClinicalTrials.gov: NCT01273792 (2010), NCT01481662 (2011), NCT06881368 (2025). (NCT01273792 chunk 1, NCT01481662 chunk 1, NCT06881368 chunk 1)

References

1. (bose2023susacsyndromeneurological pages 1-2): Smriti Bose, Athanasios Papathanasiou, Sameep Karkhanis, Jason P. Appleton, Dominic King, Ruchika Batra, Susan P. Mollan, and Saiju Jacob. Susac syndrome: neurological update (clinical features, long-term observational follow-up and management of sixteen patients). Journal of Neurology, 270:6193-6206, Aug 2023. URL: https://doi.org/10.1007/s00415-023-11891-z, doi:10.1007/s00415-023-11891-z. This article has 28 citations and is from a domain leading peer-reviewed journal.

2. (david2022susacsyndromea pages 1-2): Clémence David, Karim Sacré, Marie-Cécile Henri-Feugeas, Isabelle Klein, Serge Doan, Fleur Aubart Cohen, Eric Jouvent, and Thomas Papo. Susac syndrome: a scoping review. Autoimmunity Reviews, 21:103097, Jun 2022. URL: https://doi.org/10.1016/j.autrev.2022.103097, doi:10.1016/j.autrev.2022.103097. This article has 55 citations and is from a peer-reviewed journal.

3. (jarius2014clinicalparaclinicaland pages 1-2): Sven Jarius, Ilka Kleffner, Jan M Dörr, Jaume Sastre-Garriga, Zsolt Illes, Eric Eggenberger, Colin Chalk, Marius Ringelstein, Orhan Aktas, Xavier Montalban, Kai Fechner, Winfried Stöcker, Erich B Ringelstein, Friedemann Paul, and Brigitte Wildemann. Clinical, paraclinical and serological findings in susac syndrome: an international multicenter study. Journal of Neuroinflammation, 11:46, Mar 2014. URL: https://doi.org/10.1186/1742-2094-11-46, doi:10.1186/1742-2094-11-46. This article has 165 citations and is from a peer-reviewed journal.

4. (bullock2023useofdisease pages 1-2): Danielle R. Bullock, Robert T. Spencer, Richard K. Vehe, Sunil Srivastava, and Robert M. Rennebohm. Use of disease assessment tools to increase the value of case reports on susac syndrome: two case reports. Journal of Medical Case Reports, Apr 2023. URL: https://doi.org/10.1186/s13256-023-03838-9, doi:10.1186/s13256-023-03838-9. This article has 2 citations and is from a peer-reviewed journal.

5. (fuchs2025clinicalcharacterizationand pages 1-2): Lior Fuchs, Adi Wilf-Yarkoni, Hadar Kolb, Ifat Vigiser, Keren Regev, Dinah Zur, Zohar Habot-Wilner, Yahav Oron, Viktoria Furer, Nitai Shimon, Mark A. Hellmann, Itay Lotan, Eitan Auriel, Robert Rennebohm, Ori Elkayam, and Arnon Karni. Clinical characterization and prognostic risk factors of susac syndrome. Neurology Neuroimmunology & Neuroinflammation, Mar 2025. URL: https://doi.org/10.1212/nxi.0000000000200357, doi:10.1212/nxi.0000000000200357. This article has 5 citations.

6. (NCT01273792 chunk 1): Jan-Markus Dörr. Investigation of Biomarkers in Susac Syndrome. Charite University, Berlin, Germany. 2010. ClinicalTrials.gov Identifier: NCT01273792

7. (NCT01481662 chunk 1): Epidemiological, Clinical and Etiological Features of SUSAC's Syndrome. Assistance Publique - Hôpitaux de Paris. 2011. ClinicalTrials.gov Identifier: NCT01481662

8. (NCT06881368 chunk 1): Phenotypic and Etiological Characterization of Susac Syndrome. Assistance Publique - Hôpitaux de Paris. 2025. ClinicalTrials.gov Identifier: NCT06881368

9. (gross2019cd8+tcellmediated pages 1-2): Catharina C. Gross, Céline Meyer, Urvashi Bhatia, Lidia Yshii, Ilka Kleffner, Jan Bauer, Anna R. Tröscher, Andreas Schulte-Mecklenbeck, Sebastian Herich, Tilman Schneider-Hohendorf, Henrike Plate, Tanja Kuhlmann, Markus Schwaninger, Wolfgang Brück, Marc Pawlitzki, David-Axel Laplaud, Delphine Loussouarn, John Parratt, Michael Barnett, Michael E. Buckland, Todd A. Hardy, Stephen W. Reddel, Marius Ringelstein, Jan Dörr, Brigitte Wildemann, Markus Kraemer, Hans Lassmann, Romana Höftberger, Eduardo Beltrán, Klaus Dornmair, Nicholas Schwab, Luisa Klotz, Sven G. Meuth, Guillaume Martin-Blondel, Heinz Wiendl, and Roland Liblau. Cd8+ t cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in susac syndrome. Nature Communications, Dec 2019. URL: https://doi.org/10.1038/s41467-019-13593-5, doi:10.1038/s41467-019-13593-5. This article has 150 citations and is from a highest quality peer-reviewed journal.

10. (seifertheld2017susacssyndromeclinical pages 6-10): Thomas Seifert-Held, Beate J. Langner-Wegscheider, Martina Komposch, Philipp Simschitz, Claudia Franta, Barbara Teuchner, Hans Offenbacher, Ferdinand Otto, Johann Sellner, Helmut Rauschka, and Franz Fazekas. Susac's syndrome: clinical course and epidemiology in a central european population. International Journal of Neuroscience, 127:776-780, Sep 2017. URL: https://doi.org/10.1080/00207454.2016.1254631, doi:10.1080/00207454.2016.1254631. This article has 65 citations and is from a peer-reviewed journal.

11. (wilfyarkoni2020increasedincidenceof pages 2-3): A. Wilf-Yarkoni, O. Elkayam, O. Elkayam, O. Aizenstein, Y. Oron, V. Furer, V. Furer, Dinah Zur, Dinah Zur, M. Goldstein, M. Goldstein, D. Barequet, D. Barequet, H. Hallevi, A. Karni, A. Karni, Z. Habot-Wilner, Z. Habot-Wilner, and K. Regev. Increased incidence of susac syndrome: a case series study. BMC Neurology, Sep 2020. URL: https://doi.org/10.1186/s12883-020-01892-0, doi:10.1186/s12883-020-01892-0. This article has 37 citations and is from a peer-reviewed journal.

12. (bose2023susacsyndromeneurological pages 6-8): Smriti Bose, Athanasios Papathanasiou, Sameep Karkhanis, Jason P. Appleton, Dominic King, Ruchika Batra, Susan P. Mollan, and Saiju Jacob. Susac syndrome: neurological update (clinical features, long-term observational follow-up and management of sixteen patients). Journal of Neurology, 270:6193-6206, Aug 2023. URL: https://doi.org/10.1007/s00415-023-11891-z, doi:10.1007/s00415-023-11891-z. This article has 28 citations and is from a domain leading peer-reviewed journal.

13. (koncz2024theneurocognitiveand pages 1-2): Rebecca Koncz, Miranda J. Say, Andrew Gleason, and Todd A. Hardy. The neurocognitive and neuropsychiatric manifestations of susac syndrome: a brief review of the literature and future directions. Neurological Sciences, 45:5181-5187, Jul 2024. URL: https://doi.org/10.1007/s10072-024-07672-9, doi:10.1007/s10072-024-07672-9. This article has 2 citations and is from a peer-reviewed journal.

14. (bose2023susacsyndromeneurological pages 5-6): Smriti Bose, Athanasios Papathanasiou, Sameep Karkhanis, Jason P. Appleton, Dominic King, Ruchika Batra, Susan P. Mollan, and Saiju Jacob. Susac syndrome: neurological update (clinical features, long-term observational follow-up and management of sixteen patients). Journal of Neurology, 270:6193-6206, Aug 2023. URL: https://doi.org/10.1007/s00415-023-11891-z, doi:10.1007/s00415-023-11891-z. This article has 28 citations and is from a domain leading peer-reviewed journal.

15. (jarius2014clinicalparaclinicaland pages 8-9): Sven Jarius, Ilka Kleffner, Jan M Dörr, Jaume Sastre-Garriga, Zsolt Illes, Eric Eggenberger, Colin Chalk, Marius Ringelstein, Orhan Aktas, Xavier Montalban, Kai Fechner, Winfried Stöcker, Erich B Ringelstein, Friedemann Paul, and Brigitte Wildemann. Clinical, paraclinical and serological findings in susac syndrome: an international multicenter study. Journal of Neuroinflammation, 11:46, Mar 2014. URL: https://doi.org/10.1186/1742-2094-11-46, doi:10.1186/1742-2094-11-46. This article has 165 citations and is from a peer-reviewed journal.

16. (cvikova2024casereportsusac pages 1-2): Martina Cviková, Jakub Štefela, Vít Všianský, Michal Dufek, Irena Doležalová, Jan Vinklárek, Roman Herzig, Markéta Zemanová, Vladimír Červeňák, Jaroslav Brichta, Veronika Bárková, David Kouřil, Petr Aulický, Pavel Filip, and Viktor Weiss. Case report: susac syndrome—two ends of the spectrum, single center case reports and review of the literature. Frontiers in Neurology, Feb 2024. URL: https://doi.org/10.3389/fneur.2024.1339438, doi:10.3389/fneur.2024.1339438. This article has 8 citations and is from a peer-reviewed journal.

17. (cvikova2024casereportsusac pages 7-8): Martina Cviková, Jakub Štefela, Vít Všianský, Michal Dufek, Irena Doležalová, Jan Vinklárek, Roman Herzig, Markéta Zemanová, Vladimír Červeňák, Jaroslav Brichta, Veronika Bárková, David Kouřil, Petr Aulický, Pavel Filip, and Viktor Weiss. Case report: susac syndrome—two ends of the spectrum, single center case reports and review of the literature. Frontiers in Neurology, Feb 2024. URL: https://doi.org/10.3389/fneur.2024.1339438, doi:10.3389/fneur.2024.1339438. This article has 8 citations and is from a peer-reviewed journal.

18. (bose2023susacsyndromeneurological pages 8-9): Smriti Bose, Athanasios Papathanasiou, Sameep Karkhanis, Jason P. Appleton, Dominic King, Ruchika Batra, Susan P. Mollan, and Saiju Jacob. Susac syndrome: neurological update (clinical features, long-term observational follow-up and management of sixteen patients). Journal of Neurology, 270:6193-6206, Aug 2023. URL: https://doi.org/10.1007/s00415-023-11891-z, doi:10.1007/s00415-023-11891-z. This article has 28 citations and is from a domain leading peer-reviewed journal.

19. (vodopivec2016treatmentofsusac pages 1-3): Ivana Vodopivec and Sashank Prasad. Treatment of susac syndrome. Current Treatment Options in Neurology, 18:1-8, Dec 2016. URL: https://doi.org/10.1007/s11940-015-0386-x, doi:10.1007/s11940-015-0386-x. This article has 48 citations and is from a peer-reviewed journal.

20. (seifertheld2017susacssyndromeclinical pages 1-6): Thomas Seifert-Held, Beate J. Langner-Wegscheider, Martina Komposch, Philipp Simschitz, Claudia Franta, Barbara Teuchner, Hans Offenbacher, Ferdinand Otto, Johann Sellner, Helmut Rauschka, and Franz Fazekas. Susac's syndrome: clinical course and epidemiology in a central european population. International Journal of Neuroscience, 127:776-780, Sep 2017. URL: https://doi.org/10.1080/00207454.2016.1254631, doi:10.1080/00207454.2016.1254631. This article has 65 citations and is from a peer-reviewed journal.

21. (cvikova2024casereportsusac media 1cd8097f): Martina Cviková, Jakub Štefela, Vít Všianský, Michal Dufek, Irena Doležalová, Jan Vinklárek, Roman Herzig, Markéta Zemanová, Vladimír Červeňák, Jaroslav Brichta, Veronika Bárková, David Kouřil, Petr Aulický, Pavel Filip, and Viktor Weiss. Case report: susac syndrome—two ends of the spectrum, single center case reports and review of the literature. Frontiers in Neurology, Feb 2024. URL: https://doi.org/10.3389/fneur.2024.1339438, doi:10.3389/fneur.2024.1339438. This article has 8 citations and is from a peer-reviewed journal.

22. (NCT06881368 chunk 2): Phenotypic and Etiological Characterization of Susac Syndrome. Assistance Publique - Hôpitaux de Paris. 2025. ClinicalTrials.gov Identifier: NCT06881368

23. (cvikova2024casereportsusac media 4d784135): Martina Cviková, Jakub Štefela, Vít Všianský, Michal Dufek, Irena Doležalová, Jan Vinklárek, Roman Herzig, Markéta Zemanová, Vladimír Červeňák, Jaroslav Brichta, Veronika Bárková, David Kouřil, Petr Aulický, Pavel Filip, and Viktor Weiss. Case report: susac syndrome—two ends of the spectrum, single center case reports and review of the literature. Frontiers in Neurology, Feb 2024. URL: https://doi.org/10.3389/fneur.2024.1339438, doi:10.3389/fneur.2024.1339438. This article has 8 citations and is from a peer-reviewed journal.

24. (cvikova2024casereportsusac media bcac5361): Martina Cviková, Jakub Štefela, Vít Všianský, Michal Dufek, Irena Doležalová, Jan Vinklárek, Roman Herzig, Markéta Zemanová, Vladimír Červeňák, Jaroslav Brichta, Veronika Bárková, David Kouřil, Petr Aulický, Pavel Filip, and Viktor Weiss. Case report: susac syndrome—two ends of the spectrum, single center case reports and review of the literature. Frontiers in Neurology, Feb 2024. URL: https://doi.org/10.3389/fneur.2024.1339438, doi:10.3389/fneur.2024.1339438. This article has 8 citations and is from a peer-reviewed journal.

25. (cvikova2024casereportsusac media 5a95f86e): Martina Cviková, Jakub Štefela, Vít Všianský, Michal Dufek, Irena Doležalová, Jan Vinklárek, Roman Herzig, Markéta Zemanová, Vladimír Červeňák, Jaroslav Brichta, Veronika Bárková, David Kouřil, Petr Aulický, Pavel Filip, and Viktor Weiss. Case report: susac syndrome—two ends of the spectrum, single center case reports and review of the literature. Frontiers in Neurology, Feb 2024. URL: https://doi.org/10.3389/fneur.2024.1339438, doi:10.3389/fneur.2024.1339438. This article has 8 citations and is from a peer-reviewed journal.

26. (david2022susacsyndromea pages 4-5): Clémence David, Karim Sacré, Marie-Cécile Henri-Feugeas, Isabelle Klein, Serge Doan, Fleur Aubart Cohen, Eric Jouvent, and Thomas Papo. Susac syndrome: a scoping review. Autoimmunity Reviews, 21:103097, Jun 2022. URL: https://doi.org/10.1016/j.autrev.2022.103097, doi:10.1016/j.autrev.2022.103097. This article has 55 citations and is from a peer-reviewed journal.